GFT505

Phase 2Small molecule

GGenfit

GFT505 is one of 171 small molecule programs targeting Insulin resistance. It is currently in Phase 2.

Indications

Total Trials

Active Trials

170

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Impaired Glucose ToleranceActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Non-Alcoholic SteatohepatitisActive, not recruiting

ObesityActive, not recruiting

Insulin ResistancePhase 2

Active, not recruiting

Impaired Glucose TolerancePhase 2

Active, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Non-Alcoholic SteatohepatitisPhase 2

Active, not recruiting

ObesityPhase 2

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

20 2

GFT505

GGenfit

Phase 2

1 3

Insulin 320

Novo Nordisk

Preclinical

43 4

Adenocard

Astellas

Preclinical

1 5

NOVOLIN R

Novo Nordisk

Preclinical

1 6

Dostinex

Golytely

Cipro

Lantus

6 10

Lixisenatide

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus1 trial

Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus

Completed·GGenfit·Phase 2·NCT01261494·97 enrolled

Insulin resistance1 trial

Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity

Completed·GGenfit·Phase 2·NCT01271777·22 enrolled

Impaired glucose tolerance1 trial

Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.

Completed·GGenfit·Phase 2·NCT01275469·47 enrolled

Obesity1 trial

Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity

Completed·GGenfit·Phase 2·NCT01271751·96 enrolled

Non-Alcoholic Steatohepatitis1 trial

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

Completed·GGenfit·Phase 2·NCT01694849·275 enrolled

2 more indications

MPA1 trial

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Completed·GGenfit·Phase 1·NCT01474161·96 enrolled

Unspecified1 trial

Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

Completed·GGenfit·Phase 1·NCT02091310·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for GFT505. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GFT505 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GFT505. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genfit company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGenfit

GFT505

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes Mellitus1 trial

Insulin resistance1 trial

Impaired glucose tolerance1 trial

Obesity1 trial

Non-Alcoholic Steatohepatitis1 trial

MPA1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News